RLS (USA) Inc., a nuclear medicine pharmacy network in the US, announced on Thursday that it has signed a new agreement with Evergreen Theragnostics, Inc., a US-based radiopharmaceutical company.

Under the agreement, RLS is to prepare, sell and distribute doses of the drug candidate OCTEVY to positron emission tomography (PET) customers across the US, if the product is approved by the Food and Drug Administration (FDA). RLS is to reconstitute, radiolabel and deliver OCTEVY doses (if approved by FDA) ordered by hospitals and independent PET centres.

OCTEVY (Kit for Preparation of Ga 68 DOTATOC Injection), is currently under evaluation by the FDA as a potential radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumours (NETs) in adult and paediatric patients.

Presently, the product is under assessment by the FDA as a potential radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localisation of somatostatin receptor positive neuroendocrine tumours (NETs) in adult and paediatric patients. The company says that if the product receives approval, it can offer an important new imaging option for healthcare providers handling NETs.

Stephen Belcher, RLS CEO, said, 'This partnership is an important step forward for RLS as we add new products to our portfolio and expand our capabilities. As RLS continues to scale for sustainable growth, partnering with innovative industry leaders like Evergreen will be key.'